cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1359Research ArticleДИСЛИПОПРОТЕИДЕМИИОпыт применения симвастатина у пациентов с заболеваниями печениSimvastatin therapy in patients with hepatic diseaseДрапкинаО. М.DrapkinaO. M.drapkina@yandex.ruКлименковА. В.KlimenkovA. V.klimenkovdoc@rbcmail.ruСуховскаяИ. И.SukhovskayaI. I.drapkina@yandex.ruИвашкинВ. Т.IvashkinV. T.drapkina@yandex.ruМосковская медицинская академия им. И.М. Сеченова, МоскваI.M. Sechenov Moscow Medical Academy, MoscowСтавропольский краевой клинический диагностический центр, СтавропольStavropol Regional Clinical Diagnostic Center, Stavropol200720102007657075Copyright © Драпкина О.М., Клименков А.В., Суховская И.И., Ивашкин В.Т., 20072007Драпкина О.М., Клименков А.В., Суховская И.И., Ивашкин В.Т.Drapkina O.M., Klimenkov A.V., Sukhovskaya I.I., Ivashkin V.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1359

Цель. Оценить эффективность, безопасность и переносимость симвастатина (Вазилип) у пациентов с дислипидемией IIа и IIб типов, имеющих сочетанную патологию печени. Материал и методы. В анализ были включены 30 больных, которым был назначен Вазилип 20 мг/сут. На первом визите в клинику, через 3, 6 и 12 месяцев терапии Вазилипом у больных брали анализы крови натощак для определения уровней общего холестерина (ОХС), триглицеридов (ТГ), ХС липопротеидов высокой плотности (ЛВП), ХС липопротеидов низкой плотности (ЛНП), а также активности аспартатаминотрансферазы (АСТ), аланинаминотрансферазы (АЛТ), билирубина, креатинина. Гиполипидемическую эффективность Вазилипа и переносимость терапии оценивали в течение 12 месяцев приема этого препарата. Результаты. Через 12 месяцев терапии Вазилипом, достоверно снизились уровни ОХС на 17,5%, ТГ – на 26,3 %, ХС ЛНП – на 27,8 %; содержание ХС ЛВП недостоверно увеличилось на 23,3%. Снижение индекса атерогенности составило 36,7%. Переносимость лечения пациентами с сопутствующей патологией печени в течение всего времени была хорошей. Достоверно значимые изменения активности АСТ, АЛТ, глюкозы, креатинина и билирубина отсутствовали. Заключение. Длительное применение (в течение 1 года) симвастатина (Вазилип) в дозе 20 мг/сут. у больных с жировым гепатозом печени безопасно и позволяет добиться хорошего терапевтического эффекта.

Aim. To assess effectiveness, safety, and tolerability of simvastatin (Vasilip) in patients with IIa and IIb dyslipidemia, as well as with hepatic disease. Material and methods. The analysis included 30 patients receiving Vasilip (20 mg/d). At baseline and after 3, 6, and 14 months of the treatment, fasting levels of total cholesterol (TCH), triglycerides (TG), high-density lipoprotein CH (HDL-CH), low-density lipoprotein CH (LDL-CH), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activity, bilirubin and creatinine were measured. Vasilip lipid-lowering effectiveness and tolerability was assessed during 12 months of the therapy. Results. After 12 months of Vasilip therapy, there was a significant reduction in TCH (17,5%), TG (26,3%), and LDL-CH (27,8%) levels; HDL-CH increase (23,3%) was not statistically significant. Atherogenicity index decreased by 36,7%. Vasilip therapy was well tolerated by individuals with hepatic pathology throughout the whole study. No significant increase in AST and ALT activity, glucose, creatinine or bilirubin levels was observed. Conclusion. Long-term (one-year) simvastatin therapy (20 mg/d) in patients with lipid hepatosis was both safe and clinically effective.

атеросклерозингибиторы 3–гидрокси–3–метилглутарил–коэнзим–А–редуктазысимвастатинжировой гепатоз печениatherosclerosis3-hydroxy-3-methylglutaryl-coenzyme-A-reductase inhibitorssimvastatinlipid hepatosisReferencesАмосова Е.Н. Атеросклероз: некоторые факты о холестерине. Ж практ врача 1996; 5: 34-8Амосова Е.Н. Атеросклероз: некоторые факты о холестерине. Ж практ врача 1996; 5: 34-8Аронов Д.М. Лечение и практика атеросклероза. Москва «Триада-Х» 2000; 411 с.Аронов Д.М. Лечение и практика атеросклероза. Москва «Триада-Х» 2000; 411 с.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.Shepherd J, Cobble SM, Ford J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.Shepherd J, Cobble SM, Ford J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Раnel III). JAMA 2001; 285: 2486-97.Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Раnel III). JAMA 2001; 285: 2486-97.Wood D, Durrington PN, Poulter N, et al. Joint British Recommendations on prevention of coronary heart disease in clinical practice on behalf of the British Cardiac society, British Hyperlipidemia Association, British Hypertension Society and endorsed by the British Diabetic Association. Heart 1998; 80(Suppl. 2): S1-29.Wood D, Durrington PN, Poulter N, et al. Joint British Recommendations on prevention of coronary heart disease in clinical practice on behalf of the British Cardiac society, British Hyperlipidemia Association, British Hypertension Society and endorsed by the British Diabetic Association. Heart 1998; 80(Suppl. 2): S1-29.Российские рекомендации, разработанные группой экспертов ВНОК. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Москва 2004.Российские рекомендации, разработанные группой экспертов ВНОК. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Москва 2004.Grundy SM. Consensus statement: role of the therapy with statins in patients with hypertriglyceridemia. Am J Cardiol 1998; 81(Suppl. 4A): 1B-6.Grundy SM. Consensus statement: role of the therapy with statins in patients with hypertriglyceridemia. Am J Cardiol 1998; 81(Suppl. 4A): 1B-6.Bakker-Arkema RG, Davidson MH, Goldstein JL, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-33.Bakker-Arkema RG, Davidson MH, Goldstein JL, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-33.Illingworth DR, Erkelens DW, Keller U, et al. Defined daily doses in relation to hypolipidemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 199-; 343: 1554-5.Illingworth DR, Erkelens DW, Keller U, et al. Defined daily doses in relation to hypolipidemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 199-; 343: 1554-5.Davidson MH, Bakker-Arkema RG, Goldstein JL, et al. Efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 79: 38-42.Davidson MH, Bakker-Arkema RG, Goldstein JL, et al. Efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 79: 38-42.MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet, 1994, 344: 633 - 638. [Erratum. Lancet 1994; 344: 762].MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet, 1994, 344: 633 - 638. [Erratum. Lancet 1994; 344: 762].Stein EA, Lane M, Laskarzewski P. Effect of statins on triglyceride level. Am J Cardiol 1998; 81(Suppl. 4A): 27B-31.Stein EA, Lane M, Laskarzewski P. Effect of statins on triglyceride level. Am J Cardiol 1998; 81(Suppl. 4A): 27B-31.Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. JAMA 1997; 278: 313-21.Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality: an overview of randomized trials. JAMA 1997; 278: 313-21.VALIANT: Nippon Rinsho. 2002; 60(10):2034-8; Am Heart J 2003;145(5): 754-7.VALIANT: Nippon Rinsho. 2002; 60(10):2034-8; Am Heart J 2003;145(5): 754-7.Сусеков А.В., Соловьева Е.Ю. Симзастатин (Зокор) 20 мг и ловастатин (Холетар) 40 мг у больных ИБС и первичной гиперхолестеринешей. Исследование эквивалентных доз. Клин фармакол тер 2001; 10(4): 1-4.Сусеков А.В., Соловьева Е.Ю. Симзастатин (Зокор) 20 мг и ловастатин (Холетар) 40 мг у больных ИБС и первичной гиперхолестеринешей. Исследование эквивалентных доз. Клин фармакол тер 2001; 10(4): 1-4.Final study report. The multiple-dose bioequivalence of two simvastatin oral formulations in healthy volunteers. Novo mesto 1998; 1-49.Final study report. The multiple-dose bioequivalence of two simvastatin oral formulations in healthy volunteers. Novo mesto 1998; 1-49.Pasternak RC, Smith SC, Bairey CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. JACC 2002; 40(3): 567-72.Pasternak RC, Smith SC, Bairey CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. JACC 2002; 40(3): 567-72.Denus S, Spinler SA, Miller K, et al. Statins and Liver Toxicity: A Meta-Analysis. Pharmacotherapy 2004; 24(5): 584-91.Denus S, Spinler SA, Miller K, et al. Statins and Liver Toxicity: A Meta-Analysis. Pharmacotherapy 2004; 24(5): 584-91.

The authors declare that there are no conflicts of interest present.